Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy.

@article{Wang2008OvercomingMI,
  title={Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy.},
  author={Xuerong Wang and Natalyn Nicole Hawk and Ping Yue and John Sae Wook Kauh and Suresh S Ramalingam and Haian Fu and Fadlo R. Khuri and Shi-yong R Sun},
  journal={Cancer biology & therapy},
  year={2008},
  volume={7 12},
  pages={1952-8}
}
The mammalian target of rapamycin (mTOR) has emerged as an important cancer therapeutic target. Several mTOR inhibitors are currently being tested in cancer clinical trials. Both PI3K/Akt and MEK/ERK signaling regulate mTOR axis. However, inhibition of mTOR activates Akt survival signaling, which in turn attenuates mTOR inhibitors' anticancer efficacy. We are interested in developing strategies for enhancing mTOR-targeted cancer therapy. In this study, we report that mTOR inhibition also… CONTINUE READING